Disclosures: Jessica Sosio: Nothing to Disclose, Karla Geisse: Nothing to Disclose, Lindsey Valdiviez: Nothing to Disclose, Roudi Bachar: Nothing to Disclose, Adrian Singson: Nothing to Disclose, Oluwagbenga Serrano: MERCK: Stock - publicly traded company 2229 ALFAPUMP SYSTEM IN REFRACTORY ASCITES: RESULTS FROM THE POSEIDON STUDY AT 24 MONTHS Hugo Vargas 1 Deepika Devuni 2 Mangesh Pagadala 3 Angela Cheung 4 Sumeet Asrani 5 Gijs Klarenbeek 6 Jeroen Capel 6 Jasmohan Bajaj 7 K Rajender Reddy 8 Patrick Kamath 9 Florence Wong 10 , 1 Mayo Clinic Arizona, 2 University of Massachusetts, 3 Methodist Transplant Center, Dallas, 4 The Ottawa Hospital, 5 Liver Consultants of Texas, 6 Sequana Medical, 7 Virginia Commonwealth University, 8 University of Pennsylvania, 9 Mayo Clinic Rochester, 10 University of Toronto Background: The standard of care for refractory ascites (RA) in cirrhosis is repeated large volume paracentesis (LVP)

GLP-1/GIP receptor agonists work by supporting pathways involved in appetite signaling, digestion, nutrient utilization, and metabolic processes
Chan, The CNC basic leucine zipper factor, Nrf1, is essential for cell survival in response to oxidative stress-inducing agents
it is just a small serving of protein